Cogent Biosciences, Inc.

NASDAQ•COGT

CEO: Mr. Andrew R. Robbins M.B.A.

板块: Healthcare

行业: Biotechnology

上市日期: 2018-03-29

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

联系方式

275 Wyman Street, 3rd Floor, Waltham, MA, 02451, United States

617-945-5576

www.cogentbio.com

市值

$6.08B

市盈率 (TTM)

-7.7

17.8

股息率

52周最高

$43.73

52周最低

$3.72

52周范围

84%

排名47Top 61.9%

3.4

F-Score

改良版 Piotroski 分析

基于 10 年期基本面

疲弱 • 3.4 / 9 分

评分区间 (0-9)

8-9: 价值优异

6-7: 基本面强劲

4-5: 整体稳健

0-3: 表现疲弱

数据范围: 2016-2025

财务仪表盘

Q4 2025 数据

营业收入

$0.00+0.00%

近4季度走势

每股收益

-$0.69+0.00%

近4季度走势

自由现金流

-$79.92M+0.00%

近4季度走势

2025 Annual 财报亮点

核心亮点

Bezuclastinib Clinical Progress Positive top-line results achieved for SM and GIST indications in 2025; NDA submission for NonAdvSM completed.

Financing Activities Strong Financing provided $878.2M in 2025, including $222.8M from Notes issuance, bolstering capital resources.

Cash Position Strong Cash, equivalents, and securities totaled $900.8M as of December 31, 2025, funding operations into 2028.

R&D Spending Increased Research and development expenses rose $37.1M to $269.78M in 2025, supporting clinical trial progression.

关注风险

Continued Net Losses Incurred Net loss reached $328.94M in 2025, increasing $73.08M from 2024; operations remain unprofitable.

Pipeline Dependency Risk Business success highly dependent on bezuclastinib program success; pipeline expansion requires substantial funding.

Manufacturing Sole Source Risk API and drug product for bezuclastinib rely on single-source suppliers; loss significantly harms business operations.

Regulatory Approval Uncertainty Regulatory plans may face disagreement from FDA; approval for all indications is not guaranteed.

前瞻展望

Commercial Launch Planned Expect US commercial launch for NonAdvSM in second half of 2026, pending successful FDA regulatory approval.

Pipeline Advancement Continues Plan to initiate Phase 1 study for ErbB2 inhibitor and submit IND for KRAS/JAK2 programs in 2026.

Future Capital Requirements Expect substantial future expenses; additional financing required to complete development and commercialization efforts.

GIST NDA Submission Target Expect to complete GIST NDA submission in April 2026, following RTOR acceptance in January 2026.

同行对比

营业收入 (TTM)

SRPT

$2.20B

+15.6%

GLPG

$1.26B

+303.5%

RCUS

$247.00M

-4.3%

毛利率 (最新季度)

LQDA

101.7%

+29.3pp

AGIO

96.9%

-4.3pp

RCUS

90.9%

-7.7pp

关键指标

股票代码	市值	市盈率 (TTM)	净资产收益率 (TTM)	负债率
IBRX	$9.21B	-25.2	64.3%	175.0%
COGT	$6.08B	-7.7	-100.2%	27.0%
DNLI	$3.08B	-6.7	-50.1%	3.7%

长期趋势

近4季度

营业收入

净利润

经营现金流

4季度营收复合增长率

N/M

营收波动较大

4季度净利润复合增长率

N/M

盈利状态转变

现金流稳定性

现金流需要关注

深度研究

下次财报:2026年5月4日

每股收益:-

营业收入:-

财务数据

电话会议

财务报告

新闻

利润表

资产负债表

现金流量表

财务比率

变化率

利润表	过去12个月

无数据